The Role of Luspatercept in the Evolving Treatment Landscape of LR-MDS

Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes (LR-MDS), with a focus on achieving hemoglobin levels ≥ 10, as highlighted by Santini et al in their ASH 2024 abstract, demonstrating the clinical significance of this target for improving patient outcomes.

EP: 1.An Overview of the Treatment Landscape for Anemia Management in LR-MDS

EP: 2.Updates From COMMANDS at ASH 2024

Now Viewing

EP: 3.The Role of Luspatercept in the Evolving Treatment Landscape of LR-MDS

Video content above is prompted by the following:

• Where do you see EMAs in the landscape of anemia management in LR-MDS?
• What are your thoughts on hemoglobin levels ≥ 10?

Recent Videos